Deletion of Dux ameliorates muscular dystrophy in mdx mice by attenuating oxidative stress via Nrf2 DOI

Siyuan Sun,

Wen Zhai,

Ruixue Zhang

et al.

The FASEB Journal, Journal Year: 2024, Volume and Issue: 38(14)

Published: July 11, 2024

Abstract DUX4 has been widely reported in facioscapulohumeral muscular dystrophy, but its role Duchenne dystrophy (DMD) is unclear. Dux the mouse paralog of DUX4. In −/− mdx mice, forelimb grip strength test and treadmill were performed, extensor digitorum longus (EDL) contraction properties measured to assess skeletal muscle function. Pathological changes mice determined by serum CK LDH levels Masson staining. Inflammatory factors, oxidative stress, mitochondrial function indicators detected using kits. Primary satellite cells isolated, antioxidant molecule Nrf2 was detected. MTT assay Edu used evaluate proliferation TUNEL for cell death. The results show that deletion enhanced EDL contractility, prolonged running time distance mice. Deleting also attenuated fibrosis, inflammation, dysfunction Furthermore, deficiency promoted survival increasing

Language: Английский

Metformin-enhances resilience via hormesis DOI Creative Commons
Edward J. Calabrese, Evgenios Agathokleous, Rachna Kapoor

et al.

Ageing Research Reviews, Journal Year: 2021, Volume and Issue: 71, P. 101418 - 101418

Published: Aug. 5, 2021

Language: Английский

Citations

19

Current insights in ultra-rare adenylosuccinate synthetase 1 myopathy – meeting report on the First Clinical and Scientific Conference. 3 June 2024, National Centre for Advancing Translational Science, Rockville, Maryland, the United States of America DOI Creative Commons
Emma Rybalka, Hyung Jun Park, Atchayaram Nalini

et al.

Orphanet Journal of Rare Diseases, Journal Year: 2024, Volume and Issue: 19(1)

Published: Nov. 26, 2024

The inaugural Clinical and Scientific Conference on Adenylosuccinate Synthetase 1 (ADSS1) myopathy was held June 3, 2024, at the National Institutes of Health (NIH) Center for Advancing Translational Sciences (NCATS) in Rockville, Maryland, USA. ADSS1 is an ultra-rare, inherited neuromuscular disease. Features geographical patient clusters South Korea, Japan, India United States America were characterised discussed. Pre-clinical animal cell-based models discussed, providing unique insight into disease pathogenesis. biochemical pathogenesis potential therapeutic targets identified. Potential clinical pre-clinical biomarkers An consortium established a roadmap development created.

Language: Английский

Citations

2

Modulation of muscle redox and protein aggregation rescues lethality caused by mutant lamins DOI Creative Commons
Gary S. Coombs, Jose L. Rios-Monterrosa, Shuping Lai

et al.

Redox Biology, Journal Year: 2021, Volume and Issue: 48, P. 102196 - 102196

Published: Nov. 25, 2021

Mutations in the human LMNA gene cause a collection of diseases called laminopathies, which includes muscular dystrophy and dilated cardiomyopathy. The encodes lamins, filamentous proteins that form meshwork on inner side nuclear envelope. How mutant lamins muscle disease is not well understood, treatment options are currently limited. To understand pathological functions so therapies can be developed, we generated new Drosophila models iPS cell-derived cardiomyocytes. In models, muscle-specific expression caused envelope defects, cytoplasmic protein aggregation, activation Nrf2/Keap1 redox pathway, reductive stress. These defects reduced larval motility death at pupal stage. Patient-derived cardiomyocytes expressing showed deformations. allowed for genetic pharmacological manipulations organismal level. Genetic interventions to increase autophagy, decrease signaling, or lower reducing equivalents partially suppressed lethality by lamins. Moreover, flies with pamoic acid, compound inhibits NADPH-producing malic enzyme, lethality. Taken together, these studies have identified multiple factors as potential therapeutic targets LMNA-associated dystrophy.

Language: Английский

Citations

15

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential DOI Creative Commons
Emma Rybalka, Stephanie Kourakis,

Charles A. Bonsett

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(6), P. 822 - 822

Published: May 31, 2023

Adenylosuccinic acid (ASA) is an orphan drug that was once investigated for clinical application in Duchenne muscular dystrophy (DMD). Endogenous ASA participates purine recycling and energy homeostasis but might also be crucial averting inflammation other forms of cellular stress during intense demand maintaining tissue biomass glucose disposal. This article documents the known biological functions explores its potential treatment neuromuscular chronic diseases.

Language: Английский

Citations

6

Deletion of Dux ameliorates muscular dystrophy in mdx mice by attenuating oxidative stress via Nrf2 DOI

Siyuan Sun,

Wen Zhai,

Ruixue Zhang

et al.

The FASEB Journal, Journal Year: 2024, Volume and Issue: 38(14)

Published: July 11, 2024

Abstract DUX4 has been widely reported in facioscapulohumeral muscular dystrophy, but its role Duchenne dystrophy (DMD) is unclear. Dux the mouse paralog of DUX4. In −/− mdx mice, forelimb grip strength test and treadmill were performed, extensor digitorum longus (EDL) contraction properties measured to assess skeletal muscle function. Pathological changes mice determined by serum CK LDH levels Masson staining. Inflammatory factors, oxidative stress, mitochondrial function indicators detected using kits. Primary satellite cells isolated, antioxidant molecule Nrf2 was detected. MTT assay Edu used evaluate proliferation TUNEL for cell death. The results show that deletion enhanced EDL contractility, prolonged running time distance mice. Deleting also attenuated fibrosis, inflammation, dysfunction Furthermore, deficiency promoted survival increasing

Language: Английский

Citations

2